TVTX · Travere Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $127.20M | - | $164.86M | $114.45M | $81.73M | - | $62.90M | $54.12M | $41.37M | - |
| Cost of Revenue | $1.95M | - | $1.58M | $1.52M | $4.68M | - | $1.63M | $2.06M | $1.50M | - |
| Gross Profit | $125.25M | - | $163.27M | $112.93M | $77.05M | - | $61.27M | $52.05M | $39.87M | - |
| R&D | $57.09M | - | $51.89M | $49.36M | $46.89M | - | $51.68M | $54.33M | $49.42M | - |
| SG&A | $80.25M | - | $86.45M | $76.22M | $72.84M | - | $65.62M | $64.78M | $64.22M | - |
| Total Operating Expenses | $164.11M | - | $139.93M | $127.10M | $124.41M | - | $119.05M | $121.82M | $180.61M | - |
| D&A | $25.21M | - | - | - | $12.80M | - | - | - | $9.88M | - |
| Operating Income | ($36.91M) | - | $24.93M | ($12.65M) | ($42.67M) | - | ($56.15M) | ($67.70M) | ($139.24M) | - |
| Interest Expense | $2.30M | - | $2.75M | $2.85M | $2.80M | - | $2.82M | $2.79M | $2.80M | - |
| Income Tax | ($120.0K) | - | $8.0K | $20.0K | $39.0K | - | ($84.0K) | $85.0K | $191.0K | - |
| Net Income | ($37.10M) | - | $25.71M | ($12.76M) | ($41.23M) | - | ($54.81M) | ($70.41M) | ($136.06M) | - |
| EPS - Basic | ($0.40) | - | $0.29 | ($0.14) | ($0.47) | - | ($0.70) | ($0.91) | ($1.76) | - |
| EPS - Diluted | ($0.40) | - | $0.28 | ($0.14) | ($0.47) | - | ($0.70) | ($0.91) | ($1.76) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $78.36M | $93.03M | $110.93M | $75.15M | $61.90M | $58.53M | $36.41M | $32.29M | $43.25M | $58.18M |
| Accounts Receivable | $87.30M | $80.13M | $82.98M | $38.72M | $34.38M | $27.12M | $25.17M | $24.47M | $22.73M | $21.18M |
| Inventory | $37.05M | $36.16M | $37.55M | $37.68M | $38.01M | $6.20M | $42.88M | $42.98M | $42.31M | $9.41M |
| Accounts Payable | $12.91M | $24.80M | $18.23M | $19.13M | $15.37M | $23.53M | $23.20M | $25.84M | $16.73M | $41.67M |
| Current Assets | $392.68M | $437.56M | $371.11M | $379.57M | $374.17M | $416.70M | $324.74M | $368.98M | $481.08M | $616.77M |
| Total Assets | $555.19M | $605.19M | $538.58M | $555.31M | $548.80M | $594.13M | $504.41M | $551.12M | $663.55M | $788.91M |
| Current Liabilities | $125.44M | $159.90M | $135.07M | $189.54M | $182.46M | $200.75M | $190.04M | $121.27M | $173.23M | $177.91M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $456.46M | $490.36M | $465.02M | $522.56M | $515.98M | $535.05M | $534.86M | $535.97M | $589.48M | $588.10M |
| Stockholders' Equity | $98.73M | $114.83M | $73.56M | $32.75M | $32.82M | $59.08M | ($30.45M) | $15.15M | $74.07M | $200.81M |
| Retained Earnings | ($1.51B) | ($1.47B) | ($1.48B) | ($1.50B) | ($1.49B) | ($1.45B) | ($1.39B) | ($1.33B) | ($1.26B) | ($1.13B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($40.37M) | - | - | - | ($42.19M) | - | - | - | ($119.00M) | - |
| Investing Cash Flow | $21.55M | - | - | - | $41.29M | - | - | - | $104.90M | - |
| Financing Cash Flow | $4.20M | - | - | - | $3.72M | - | - | - | ($525.0K) | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($119.00M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 98.5% | - | 99.0% | 98.7% | 94.3% | - | 97.4% | 96.2% | 96.4% | - |
| Operating margin | -29.0% | - | 15.1% | -11.1% | -52.2% | - | -89.3% | -125.1% | -336.5% | - |
| EBITDA margin | -9.2% | - | - | - | -36.5% | - | - | - | -312.7% | - |
| Net margin | -29.2% | - | 15.6% | -11.1% | -50.4% | - | -87.1% | -130.1% | -328.9% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -287.6% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.87 | - |
| R&D / Revenue | 44.9% | - | 31.5% | 43.1% | 57.4% | - | 82.2% | 100.4% | 119.4% | - |
| SG&A / Revenue | 63.1% | - | 52.4% | 66.6% | 89.1% | - | 104.3% | 119.7% | 155.2% | - |
| Effective tax rate | - | - | 0.0% | - | - | - | - | - | - | - |
| Return on assets | -6.7% | - | 4.8% | -2.3% | -7.5% | - | -10.9% | -12.8% | -20.5% | - |
| Return on equity | -37.6% | - | 34.9% | -39.0% | -125.6% | - | 180.0% | -464.8% | -183.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.13 | 2.74 | 2.75 | 2.00 | 2.05 | 2.08 | 1.71 | 3.04 | 2.78 | 3.47 |
| Quick ratio | 2.84 | 2.51 | 2.47 | 1.80 | 1.84 | 2.04 | 1.48 | 2.69 | 2.53 | 3.41 |
| Cash ratio | 0.62 | 0.58 | 0.82 | 0.40 | 0.34 | 0.29 | 0.19 | 0.27 | 0.25 | 0.33 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -16.1x | - | 9.1x | -4.4x | -15.2x | - | -19.9x | -24.3x | -49.7x | - |
| Equity multiplier | 5.62 | 5.27 | 7.32 | 16.96 | 16.72 | 10.06 | -16.56 | 36.38 | 8.96 | 3.93 |
| Liabilities / Assets | 0.82 | 0.81 | 0.86 | 0.94 | 0.94 | 0.90 | 1.06 | 0.97 | 0.89 | 0.75 |
| Efficiency | ||||||||||
| Asset turnover | 0.23 | - | 0.31 | 0.21 | 0.15 | - | 0.12 | 0.10 | 0.06 | - |
| Inventory turnover | 0.05 | - | 0.04 | 0.04 | 0.12 | - | 0.04 | 0.05 | 0.04 | - |
| Days sales outstanding | 251d | - | 184d | 123d | 154d | - | 146d | 165d | 201d | - |
| Days inventory outstanding | 6936d | - | 8646d | 9042d | 2965d | - | 9625d | 7612d | 10267d | - |
| Days payable outstanding | 2417d | - | 4197d | 4592d | 1199d | - | 5207d | 4577d | 4059d | - |
| Cash conversion cycle | 4769d | - | 4633d | 4574d | 1919d | - | 4564d | 3200d | 6409d | - |
| Valuation | ||||||||||
| P / E | - | - | 85.4x | - | - | - | - | - | - | - |
| P / B | 27.6x | - | 33.3x | 40.2x | 48.2x | - | - | 42.1x | 8.0x | - |
| P / S | 21.5x | - | 14.9x | 11.5x | 19.4x | - | 17.3x | 11.8x | 14.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 55.6% | - | 162.1% | 111.5% | 97.5% | - | 69.6% | -9.3% | -27.4% | - |
| Revenue CAGR (3y) | 30.7% | - | 45.5% | 28.3% | 19.0% | - | -2.7% | -0.3% | -4.4% | - |
| Revenue CAGR (5y) | 21.8% | - | 26.4% | 18.8% | 11.3% | - | 7.2% | 3.9% | 0.9% | - |
| Gross profit growth (YoY) | 62.5% | - | 166.5% | 116.9% | 93.3% | - | 71.1% | -9.8% | -23.1% | - |
| Operating income growth (YoY) | 13.5% | - | - | 81.3% | 69.4% | - | 39.4% | 22.7% | -60.0% | - |
| Net income growth (YoY) | 10.0% | - | - | 81.9% | 69.7% | - | - | 17.8% | -57.6% | - |
| EPS growth (YoY) | 14.9% | - | - | 84.6% | 73.3% | - | - | 19.5% | -38.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | -45.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 200.8% | 94.4% | - | 116.2% | -55.7% | -70.6% | - | -87.0% | -60.8% | 368.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$490.73M totalReportable Segment$490.73M · 100.0%
Product / service
$964.59M totalProduct$410.46M · 42.6%
FILSPARI$322.00M · 33.4%
Tiopronin Products$88.45M · 9.2%
License$80.27M · 8.3%
Market Access Milestone$40.00M · 4.1%
Regulatory Milestone$17.50M · 1.8%
Royalty$5.90M · 0.6%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Travere Therapeutics against the 5 most active filers in the same SIC group.